Recombinant Human Milr1 protein

中文名： 过敏原-1(Milr1)重组蛋白
别名： Milr1；C17orf60；MCA32；Allergin-1

货号: PA2000-3085

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	Milr1
Uniprot No	Q7Z6M3
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	249-343aa
氨基酸序列	LPKYKTRKAMRNNVPRDRGDTAMEVGIYANILEKQAKEESVPEVGSRPCVSTAQDEAKHSQELQYATPVFQEVAPREQEACDSYKSGYVYSELNF
预测分子量	26.1 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于Milr1重组蛋白的模拟参考文献示例(请注意，这些文献为虚构内容，实际研究中请通过学术数据库查询真实文献)：

---

1. **文献名称**：Structural and Functional Characterization of Recombinant Milr1 in Immune Regulation

**作者**：Li, X. et al.

**摘要**：本研究解析了重组Milr1蛋白的晶体结构，发现其通过结合特定免疫细胞表面受体调控T细胞活性，揭示了其在炎症反应中的潜在作用机制。

2. **文献名称**：Expression and Purification of Functional Milr1 Recombinant Protein in Mammalian Cells

**作者**：Wang, Y. et al.

**摘要**：开发了一种高效表达和纯化Milr1重组蛋白的方法，验证了其在体外模型中抑制肿瘤细胞增殖的功能，为癌症免疫治疗研究提供工具。

3. **文献名称**：Milr1 Recombinant Protein Modulates Allergic Responses in Murine Models

**作者**：Tanaka, K. et al.

**摘要**：通过动物实验证明，外源性Milr1重组蛋白可减轻过敏性哮喘症状，其机制与调节Th2细胞分化和抑制IL-4分泌相关。

4. **文献名称**：Milr1 Interaction Network Revealed by Recombinant Protein-Based Proteomic Screening

**作者**：Johnson, R. et al.

**摘要**：利用重组Milr1蛋白进行蛋白质互作组分析，鉴定了多个新型结合伴侣，提示其在先天免疫信号通路中的多效性功能。

---

如需查找真实文献，建议使用PubMed、Web of Science或Google Scholar，以关键词“Milr1 recombinant protein”或“MILR1 immune function”进行检索。

背景信息

**Background of MILR1 Recombinant Protein**

MILR1 (Mast cell immunoglobulin-like receptor 1), also known as Allergin-1. is an immunomodulatory transmembrane protein predominantly expressed on mast cells and myeloid cells. It belongs to the immunoglobulin (Ig) superfamily and contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic domain, enabling it to regulate immune responses through inhibitory signaling pathways. MILR1 interacts with ligands such as IgE-antigen complexes, playing a critical role in suppressing hypersensitivity reactions and allergic inflammation.

Research has shown that MILR1 acts as a negative regulator of mast cell activation. Upon ligand binding, it recruits phosphatases like SHP-1/SHP-2. which dephosphorylate key signaling molecules, thereby dampening FcεRI-mediated signaling. This mechanism helps limit excessive mast cell degranulation, cytokine release, and anaphylactic responses. Dysregulation of MILR1 has been implicated in allergic diseases, including asthma and atopic dermatitis, highlighting its therapeutic potential.

The recombinant MILR1 protein is engineered *in vitro* using expression systems like *E. coli* or mammalian cells, ensuring proper post-translational modifications for functional studies. It retains the extracellular Ig-like domains necessary for ligand interaction, enabling applications in binding assays, structural studies, and inhibitor screening. MILR1 recombinant proteins are vital tools for deciphering its role in immune tolerance, allergy pathogenesis, and mast cell biology.

Recent studies also explore MILR1's involvement in cancer immunity and infections, as its regulatory functions may influence tumor microenvironments or pathogen responses. By leveraging recombinant MILR1. researchers aim to develop targeted therapies for allergic disorders and immune-related diseases, bridging gaps between molecular mechanisms and clinical interventions.